Valeant Pharmaceuticals International, Inc. (NYSE: VRX) Vs. Industry Vs. Sector Growth Analysis

VRX Price Chart

The compiled data also includes analyst target price and earnings per share projections. The company had revenue of $2479.60 million for the quarter, compared to analysts expectations of $2508.67 million. (NYSE: VRX). These ratios are important while doing the valuation of the company or the shares of the company. It maintained return on assets (ROA) for the last twelve months at -4.70%. The company had Year Ago Sales of 2.79 Billion. According to these analysts, the Low Revenue Estimate for Valeant Pharmaceuticals International, 2.28 Billion and the High Revenue Estimate is 2.5 Billion.

The 52 week high of Valeant Pharmaceuticals's shares is 105.93 whilst the 52-week low for shares in the company is 13.

Piper Jaffray noted a target price of 11 on Valeant Pharmaceuticals's shares. It operates through two segments: Developed markets and Emerging markets.

Valeant Pharmaceuticals Intl Inc opened for trading at $14.69 and hit $15.345 on the upside on Tuesday, eventually ending the session at $15.24, with a gain of 4.96% or 0.72 points. (NYSE: VRX) now has P/E (Price to Earnings) ratio of 0 while the company's industry has 29.51 P/E and the sector P/E is 30.43. The average true range of the stock is observed at 0.74 and the relative strength index of the stock is recorded at 52.05. Following this rating scale, a score of 1 would represent a Strong Buy, and a score of 5 would indicate a Strong Sell.

Let's have a look at some of the important valuation ratios of the Valeant Pharmaceuticals International, Inc. The highest and lowest price target given by the brokerage firms to the equity are $55 and $9, respectively. Wells Fargo & Co. reiterated a sell rating and issued a $19.50 price target on shares of Valeant Pharmaceuticals International in a research note on Sunday, September 18th. (NYSE: VRX) fell -84.53 percent over the past one year, while it rose 4.96 percent year to date (YTD). Analyst's mean target price for AGRX is $16.20 while analysts mean recommendation is 1.50.

Celgene Corporation (NASDAQ: CELG) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 2.53% to $118.68. The stock's weekly volatility was 3.43% and the RSI amounts to 37.00. The stock is now trading -8.36 percent higher from its SMA-50. The high end of the earnings forecast is $1.35 per share and low end is $0.2 per share. Scotiabank restated a sector perform rating and set a $17.00 target price (down from $32.00) on shares of Valeant Pharmaceuticals International in a research report on Thursday, November 10th. For the current year, analysts are predicting earnings of $1.91 per share according to First Call. (NYSE: VRX) has a Return on Assets of -4.7 percent, Return on Equity of -42.9 percent, while Return on Investment of 3.7 percent. The high end of the revenue guidance is $2.36 Billion and the low end is $2.14 Billion. They are projecting Next Quarter growth of -13.4%.

Valeant Pharmaceuticals International, now showing -46.5% EPS growth this year.



Latest news

Ruth Negga nominated for EE Rising Star award at the Baftas
The voting is now open online and the victor will be announced at the EE British Academy Film Awards on Sunday, February 12, 2017. The duo play Mildred and Richard Loving , the couple behind the pivotal 1967 civil rights case that changed US history.

Sky Mobile to allow customers to keep unused data
Later in 2017, the company says that it will be offering top handsets from the likes of Samsung and Apple later this year. The data packages start at £10 a month for 1GB, £15 for 2GB and £20 for 5GB.

Economy grew '0.5%' in final quarter to defy Brexit gloom - PMI
The index rose for the third consecutive month to 56.2, from 55.2 in November, the fastest expansion since July 2015. Similar PMI surveys of manufacturing and construction earlier this week also pointed to decent growth in December.

The Legend of Zelda: Won't Go Missing Again
An exact date hasn't been given, but somewhere around the game's release would be a pretty safe bet. Vociferous discussions within Nintendo on launch timings are not unprecedented.

Other news